Loading…
Associations between plasma markers and symptoms of anxiety and depression in patients with breast cancer
Among patients with solid tumors, those with breast cancer (BC) experience the most severe psychological issues, exhibiting a high global prevalence of depression that negatively impacts prognosis. Depression can be easily missed, and clinical markers for its diagnosis are lacking. Therefore, this s...
Saved in:
| Published in: | BMC psychiatry 2024-10, Vol.24 (1), p.678-15, Article 678 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c389t-cc30cf0207e67ac6b349462b2a4e921549c19a102e27d6a2d2b1e2506280d08a3 |
| container_end_page | 15 |
| container_issue | 1 |
| container_start_page | 678 |
| container_title | BMC psychiatry |
| container_volume | 24 |
| creator | He, Yibo Cheng, Shangping Yang, Lingrong Ding, Lingyu Chen, Yidan Lu, Jing Zheng, Ruzhen |
| description | Among patients with solid tumors, those with breast cancer (BC) experience the most severe psychological issues, exhibiting a high global prevalence of depression that negatively impacts prognosis. Depression can be easily missed, and clinical markers for its diagnosis are lacking. Therefore, this study in order to investigate the diagnostic markers for BC patients with depression and anxiety and explore the specific changes of metabolism.
Thirty-eight BC patients and thirty-six matched healthy controls were included in the study. The anxiety and depression symptoms of the participants were evaluated by the 17-item Hamilton Depression Scale (HAMD-17) and Hamilton Anxiety Scale (HAMA). Plasma levels of glial fibrillary acidic protein (GFAP) and lipocalin-2 (LCN2) were evaluated using enzyme linked immunosorbent assay, and plasma lactate levels and metabolic characteristics were analyzed.
This study revealed that GFAP and LCN2 may be good diagnostic markers for anxiety or depression in patients with BC and that plasma lactate levels are also a good diagnostic marker for anxiety. In addition, specific changes in metabolism in patients with BC were preliminarily explored. |
| doi_str_mv | 10.1186/s12888-024-06143-x |
| format | article |
| fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_b5225537ad6349df85cc274db563e924</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A811961203</galeid><doaj_id>oai_doaj_org_article_b5225537ad6349df85cc274db563e924</doaj_id><sourcerecordid>A811961203</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-cc30cf0207e67ac6b349462b2a4e921549c19a102e27d6a2d2b1e2506280d08a3</originalsourceid><addsrcrecordid>eNptUk1v1DAUjBCIlsIf4IAsceGS4uevOMdVBW2lSlxA4mY59kvxksSL7VV3_z3ubikfQj7YbzQzzyNN07wGeg6g1fsMTGvdUiZaqkDwdvekOQXRQcuE-Pr0j_dJ8yLnNaXQaQnPmxPe815IBadNWOUcXbAlxCWTAcsd4kI2k82zJbNN3zFlYhdP8n7elDhnEsc67wKW_QH3uEmYc5WTUIXVCJeSyV0o38iQ0OZCnF0cppfNs9FOGV893GfNl48fPl9ctTefLq8vVjet47ovrXOcupEy2qHqrFMDF71QbGBWYM9Ait5Bb4EyZJ1Xlnk2ADJJFdPUU235WXN99PXRrs0mhZpib6IN5gDEdGtsKsFNaAbJmJS8s17VLX7U0jnWCT9IxesyUb3eHb02Kf7YYi5mDtnhNNkF4zYbDiC7DqRklfr2H-o6btNSk1YWUwIU5fCbdWvr_rCMsSTr7k3NSgP0ChjllXX-H1Y9Hufg4oJjqPhfAnYUuBRzTjg-5gZq7rtijl0xtSvm0BWzq6I3Dz_eDjP6R8mvcvCf-dG4Iw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3126416031</pqid></control><display><type>article</type><title>Associations between plasma markers and symptoms of anxiety and depression in patients with breast cancer</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><creator>He, Yibo ; Cheng, Shangping ; Yang, Lingrong ; Ding, Lingyu ; Chen, Yidan ; Lu, Jing ; Zheng, Ruzhen</creator><creatorcontrib>He, Yibo ; Cheng, Shangping ; Yang, Lingrong ; Ding, Lingyu ; Chen, Yidan ; Lu, Jing ; Zheng, Ruzhen</creatorcontrib><description>Among patients with solid tumors, those with breast cancer (BC) experience the most severe psychological issues, exhibiting a high global prevalence of depression that negatively impacts prognosis. Depression can be easily missed, and clinical markers for its diagnosis are lacking. Therefore, this study in order to investigate the diagnostic markers for BC patients with depression and anxiety and explore the specific changes of metabolism.
Thirty-eight BC patients and thirty-six matched healthy controls were included in the study. The anxiety and depression symptoms of the participants were evaluated by the 17-item Hamilton Depression Scale (HAMD-17) and Hamilton Anxiety Scale (HAMA). Plasma levels of glial fibrillary acidic protein (GFAP) and lipocalin-2 (LCN2) were evaluated using enzyme linked immunosorbent assay, and plasma lactate levels and metabolic characteristics were analyzed.
This study revealed that GFAP and LCN2 may be good diagnostic markers for anxiety or depression in patients with BC and that plasma lactate levels are also a good diagnostic marker for anxiety. In addition, specific changes in metabolism in patients with BC were preliminarily explored.</description><identifier>ISSN: 1471-244X</identifier><identifier>EISSN: 1471-244X</identifier><identifier>DOI: 10.1186/s12888-024-06143-x</identifier><identifier>PMID: 39394561</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Adult ; Amino acids ; Anxiety ; Anxiety - blood ; Anxiety - diagnosis ; Anxiety - psychology ; Biomarkers ; Biomarkers - blood ; Breast cancer ; Breast Neoplasms - blood ; Breast Neoplasms - complications ; Breast Neoplasms - psychology ; Cancer patients ; Case-Control Studies ; Cell growth ; Complications and side effects ; Depression - blood ; Depression - diagnosis ; Depression, Mental ; Development and progression ; Diagnosis ; Discriminant analysis ; Enzyme-linked immunosorbent assay ; Enzymes ; Female ; Glial fibrillary acidic protein ; Glial Fibrillary Acidic Protein - blood ; Glycoproteins ; Health aspects ; Humans ; Intermediate filament proteins ; Lactic acid ; Lactic Acid - blood ; Lipocalin ; Lipocalin-2 - blood ; Measurement ; Medical diagnosis ; Medical research ; Medicine, Experimental ; Mental depression ; Mental disorders ; Mental health ; Metabolism ; Middle Aged ; Mood ; Neurophysiology ; Neutrophils ; Patients ; Physiological aspects ; Plasma ; Plasma levels ; Prognosis ; Proteins ; Psychiatric Status Rating Scales ; Psychological aspects ; Risk factors ; Solid tumors ; Tomography ; Tumors ; Womens health</subject><ispartof>BMC psychiatry, 2024-10, Vol.24 (1), p.678-15, Article 678</ispartof><rights>2024. The Author(s).</rights><rights>COPYRIGHT 2024 BioMed Central Ltd.</rights><rights>2024. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c389t-cc30cf0207e67ac6b349462b2a4e921549c19a102e27d6a2d2b1e2506280d08a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/3126416031?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,37013,44590</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39394561$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>He, Yibo</creatorcontrib><creatorcontrib>Cheng, Shangping</creatorcontrib><creatorcontrib>Yang, Lingrong</creatorcontrib><creatorcontrib>Ding, Lingyu</creatorcontrib><creatorcontrib>Chen, Yidan</creatorcontrib><creatorcontrib>Lu, Jing</creatorcontrib><creatorcontrib>Zheng, Ruzhen</creatorcontrib><title>Associations between plasma markers and symptoms of anxiety and depression in patients with breast cancer</title><title>BMC psychiatry</title><addtitle>BMC Psychiatry</addtitle><description>Among patients with solid tumors, those with breast cancer (BC) experience the most severe psychological issues, exhibiting a high global prevalence of depression that negatively impacts prognosis. Depression can be easily missed, and clinical markers for its diagnosis are lacking. Therefore, this study in order to investigate the diagnostic markers for BC patients with depression and anxiety and explore the specific changes of metabolism.
Thirty-eight BC patients and thirty-six matched healthy controls were included in the study. The anxiety and depression symptoms of the participants were evaluated by the 17-item Hamilton Depression Scale (HAMD-17) and Hamilton Anxiety Scale (HAMA). Plasma levels of glial fibrillary acidic protein (GFAP) and lipocalin-2 (LCN2) were evaluated using enzyme linked immunosorbent assay, and plasma lactate levels and metabolic characteristics were analyzed.
This study revealed that GFAP and LCN2 may be good diagnostic markers for anxiety or depression in patients with BC and that plasma lactate levels are also a good diagnostic marker for anxiety. In addition, specific changes in metabolism in patients with BC were preliminarily explored.</description><subject>Adult</subject><subject>Amino acids</subject><subject>Anxiety</subject><subject>Anxiety - blood</subject><subject>Anxiety - diagnosis</subject><subject>Anxiety - psychology</subject><subject>Biomarkers</subject><subject>Biomarkers - blood</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - blood</subject><subject>Breast Neoplasms - complications</subject><subject>Breast Neoplasms - psychology</subject><subject>Cancer patients</subject><subject>Case-Control Studies</subject><subject>Cell growth</subject><subject>Complications and side effects</subject><subject>Depression - blood</subject><subject>Depression - diagnosis</subject><subject>Depression, Mental</subject><subject>Development and progression</subject><subject>Diagnosis</subject><subject>Discriminant analysis</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Enzymes</subject><subject>Female</subject><subject>Glial fibrillary acidic protein</subject><subject>Glial Fibrillary Acidic Protein - blood</subject><subject>Glycoproteins</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Intermediate filament proteins</subject><subject>Lactic acid</subject><subject>Lactic Acid - blood</subject><subject>Lipocalin</subject><subject>Lipocalin-2 - blood</subject><subject>Measurement</subject><subject>Medical diagnosis</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Mental depression</subject><subject>Mental disorders</subject><subject>Mental health</subject><subject>Metabolism</subject><subject>Middle Aged</subject><subject>Mood</subject><subject>Neurophysiology</subject><subject>Neutrophils</subject><subject>Patients</subject><subject>Physiological aspects</subject><subject>Plasma</subject><subject>Plasma levels</subject><subject>Prognosis</subject><subject>Proteins</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychological aspects</subject><subject>Risk factors</subject><subject>Solid tumors</subject><subject>Tomography</subject><subject>Tumors</subject><subject>Womens health</subject><issn>1471-244X</issn><issn>1471-244X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptUk1v1DAUjBCIlsIf4IAsceGS4uevOMdVBW2lSlxA4mY59kvxksSL7VV3_z3ubikfQj7YbzQzzyNN07wGeg6g1fsMTGvdUiZaqkDwdvekOQXRQcuE-Pr0j_dJ8yLnNaXQaQnPmxPe815IBadNWOUcXbAlxCWTAcsd4kI2k82zJbNN3zFlYhdP8n7elDhnEsc67wKW_QH3uEmYc5WTUIXVCJeSyV0o38iQ0OZCnF0cppfNs9FOGV893GfNl48fPl9ctTefLq8vVjet47ovrXOcupEy2qHqrFMDF71QbGBWYM9Ait5Bb4EyZJ1Xlnk2ADJJFdPUU235WXN99PXRrs0mhZpib6IN5gDEdGtsKsFNaAbJmJS8s17VLX7U0jnWCT9IxesyUb3eHb02Kf7YYi5mDtnhNNkF4zYbDiC7DqRklfr2H-o6btNSk1YWUwIU5fCbdWvr_rCMsSTr7k3NSgP0ChjllXX-H1Y9Hufg4oJjqPhfAnYUuBRzTjg-5gZq7rtijl0xtSvm0BWzq6I3Dz_eDjP6R8mvcvCf-dG4Iw</recordid><startdate>20241011</startdate><enddate>20241011</enddate><creator>He, Yibo</creator><creator>Cheng, Shangping</creator><creator>Yang, Lingrong</creator><creator>Ding, Lingyu</creator><creator>Chen, Yidan</creator><creator>Lu, Jing</creator><creator>Zheng, Ruzhen</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>DOA</scope></search><sort><creationdate>20241011</creationdate><title>Associations between plasma markers and symptoms of anxiety and depression in patients with breast cancer</title><author>He, Yibo ; Cheng, Shangping ; Yang, Lingrong ; Ding, Lingyu ; Chen, Yidan ; Lu, Jing ; Zheng, Ruzhen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-cc30cf0207e67ac6b349462b2a4e921549c19a102e27d6a2d2b1e2506280d08a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Amino acids</topic><topic>Anxiety</topic><topic>Anxiety - blood</topic><topic>Anxiety - diagnosis</topic><topic>Anxiety - psychology</topic><topic>Biomarkers</topic><topic>Biomarkers - blood</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - blood</topic><topic>Breast Neoplasms - complications</topic><topic>Breast Neoplasms - psychology</topic><topic>Cancer patients</topic><topic>Case-Control Studies</topic><topic>Cell growth</topic><topic>Complications and side effects</topic><topic>Depression - blood</topic><topic>Depression - diagnosis</topic><topic>Depression, Mental</topic><topic>Development and progression</topic><topic>Diagnosis</topic><topic>Discriminant analysis</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Enzymes</topic><topic>Female</topic><topic>Glial fibrillary acidic protein</topic><topic>Glial Fibrillary Acidic Protein - blood</topic><topic>Glycoproteins</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Intermediate filament proteins</topic><topic>Lactic acid</topic><topic>Lactic Acid - blood</topic><topic>Lipocalin</topic><topic>Lipocalin-2 - blood</topic><topic>Measurement</topic><topic>Medical diagnosis</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Mental depression</topic><topic>Mental disorders</topic><topic>Mental health</topic><topic>Metabolism</topic><topic>Middle Aged</topic><topic>Mood</topic><topic>Neurophysiology</topic><topic>Neutrophils</topic><topic>Patients</topic><topic>Physiological aspects</topic><topic>Plasma</topic><topic>Plasma levels</topic><topic>Prognosis</topic><topic>Proteins</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychological aspects</topic><topic>Risk factors</topic><topic>Solid tumors</topic><topic>Tomography</topic><topic>Tumors</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>He, Yibo</creatorcontrib><creatorcontrib>Cheng, Shangping</creatorcontrib><creatorcontrib>Yang, Lingrong</creatorcontrib><creatorcontrib>Ding, Lingyu</creatorcontrib><creatorcontrib>Chen, Yidan</creatorcontrib><creatorcontrib>Lu, Jing</creatorcontrib><creatorcontrib>Zheng, Ruzhen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Open Access: DOAJ - Directory of Open Access Journals</collection><jtitle>BMC psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>He, Yibo</au><au>Cheng, Shangping</au><au>Yang, Lingrong</au><au>Ding, Lingyu</au><au>Chen, Yidan</au><au>Lu, Jing</au><au>Zheng, Ruzhen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Associations between plasma markers and symptoms of anxiety and depression in patients with breast cancer</atitle><jtitle>BMC psychiatry</jtitle><addtitle>BMC Psychiatry</addtitle><date>2024-10-11</date><risdate>2024</risdate><volume>24</volume><issue>1</issue><spage>678</spage><epage>15</epage><pages>678-15</pages><artnum>678</artnum><issn>1471-244X</issn><eissn>1471-244X</eissn><abstract>Among patients with solid tumors, those with breast cancer (BC) experience the most severe psychological issues, exhibiting a high global prevalence of depression that negatively impacts prognosis. Depression can be easily missed, and clinical markers for its diagnosis are lacking. Therefore, this study in order to investigate the diagnostic markers for BC patients with depression and anxiety and explore the specific changes of metabolism.
Thirty-eight BC patients and thirty-six matched healthy controls were included in the study. The anxiety and depression symptoms of the participants were evaluated by the 17-item Hamilton Depression Scale (HAMD-17) and Hamilton Anxiety Scale (HAMA). Plasma levels of glial fibrillary acidic protein (GFAP) and lipocalin-2 (LCN2) were evaluated using enzyme linked immunosorbent assay, and plasma lactate levels and metabolic characteristics were analyzed.
This study revealed that GFAP and LCN2 may be good diagnostic markers for anxiety or depression in patients with BC and that plasma lactate levels are also a good diagnostic marker for anxiety. In addition, specific changes in metabolism in patients with BC were preliminarily explored.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>39394561</pmid><doi>10.1186/s12888-024-06143-x</doi><tpages>15</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1471-244X |
| ispartof | BMC psychiatry, 2024-10, Vol.24 (1), p.678-15, Article 678 |
| issn | 1471-244X 1471-244X |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_b5225537ad6349df85cc274db563e924 |
| source | Open Access: PubMed Central; Publicly Available Content Database (Proquest) (PQ_SDU_P3) |
| subjects | Adult Amino acids Anxiety Anxiety - blood Anxiety - diagnosis Anxiety - psychology Biomarkers Biomarkers - blood Breast cancer Breast Neoplasms - blood Breast Neoplasms - complications Breast Neoplasms - psychology Cancer patients Case-Control Studies Cell growth Complications and side effects Depression - blood Depression - diagnosis Depression, Mental Development and progression Diagnosis Discriminant analysis Enzyme-linked immunosorbent assay Enzymes Female Glial fibrillary acidic protein Glial Fibrillary Acidic Protein - blood Glycoproteins Health aspects Humans Intermediate filament proteins Lactic acid Lactic Acid - blood Lipocalin Lipocalin-2 - blood Measurement Medical diagnosis Medical research Medicine, Experimental Mental depression Mental disorders Mental health Metabolism Middle Aged Mood Neurophysiology Neutrophils Patients Physiological aspects Plasma Plasma levels Prognosis Proteins Psychiatric Status Rating Scales Psychological aspects Risk factors Solid tumors Tomography Tumors Womens health |
| title | Associations between plasma markers and symptoms of anxiety and depression in patients with breast cancer |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T16%3A45%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Associations%20between%20plasma%20markers%20and%20symptoms%20of%20anxiety%20and%20depression%20in%20patients%20with%20breast%20cancer&rft.jtitle=BMC%20psychiatry&rft.au=He,%20Yibo&rft.date=2024-10-11&rft.volume=24&rft.issue=1&rft.spage=678&rft.epage=15&rft.pages=678-15&rft.artnum=678&rft.issn=1471-244X&rft.eissn=1471-244X&rft_id=info:doi/10.1186/s12888-024-06143-x&rft_dat=%3Cgale_doaj_%3EA811961203%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c389t-cc30cf0207e67ac6b349462b2a4e921549c19a102e27d6a2d2b1e2506280d08a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3126416031&rft_id=info:pmid/39394561&rft_galeid=A811961203&rfr_iscdi=true |